

Responsabili Scientifici

Dott. Vincenzo Andreone - Dott.ssa Stefania Miniello

Comitato scientifico

R. Acampora, F. Barra, F. Bonifacio, P. Candelaresi,
C. Capezzuto, C. Cuccurullo, G. De Joanna,
A. De Martino, A. De Mase, E. Di Battista, W. Di Iorio,
C. Di Monaco, A. Di Pietro, L. Lombardi, K. Longo,
G. Martusciello, M. Massarelli, C. Maurea,
G. Piccirillo, A. Ranieri, R. Renna, A. Sagnelli,
S. Salvatore, E. Spina.

E.C.M.

Il Workshop è stato accreditato presso il
Ministero della Salute nell'ambito del programma ECM,
consentirà pertanto di acquisire crediti formativi

Riferimenti ECM

Congresso rivolto a:

Medico Chirurgo

(Medicina e Chirurgia di Accettazione e di Urgenza;
Medicina Interna; Neurologia;
Psichiatria; Reumatologia);

Farmacista

(Farmacista Pubblico Del Ssn; Farmacista Territoriale)

Fisioterapista

Infermiere

Tecnico Di Neurofisiopatologia

N. ECM 6331- 446759

N. 8 ore formative

Nr. Crediti 8

Area Formativa

Acquisizione competenze di processo

Obiettivo formativo N. 3

Documentazione clinica.

Percorsi clinico-assistenziali diagnostici e riabilitativi,
profili di assistenza - profili di cura

Provider e Segreteria Organizzativa



Centro Direzionale Isola E3 - 80143 Napoli
tel. 081.7879520 (int. 4)
congressi@ecmnetwork.it
www.ecmnetwork.it

UPDATE ON OPINABILITY AREAS IN NEUROLOGY



20 maggio 2025

Palazzo Alabardieri
Napoli

Con il contributo non condizionante di:



E.C.M.
Educazione Continua in Medicina



Programma

08.15	Participant registration
	Greetings of the Authorities and Opening the Congress <i>A. D'Amore - M. Mensorio - G. Gubitosa - A. Annechiarico</i>
08.30	Introduction and welcome remarks <i>V. Andreone - S. Miniello</i>
SESSION 1: STROKE AND EPILEPSY <i>Chair: M. Idone - R. Renna - G. Tedeschi</i>	
09.00	Reperfusion therapies in Large Core/Low ASPECTS: does the outcome worth the effort? <i>E. Spina</i>
09.15	Antithrombotic treatment in silent cerebral infarcts and vascular dementia: good or bad old habits? <i>A. Di Pietro</i>
09.30	How quickly and to what extent should lipid-lowering therapy be initiated after a stroke? <i>C. Maurea</i>
09.45	Antithrombotic therapy in cerebral amyloid angiopathy and after intracerebral hemorrhage: still walking on eggshells? <i>M. Di Gregorio</i>
10.00	Is there an ideal drug for seizure cluster? <i>G. Piccirillo</i>
10.15	Are emerging therapies ready to bridge the gap between groundbreaking research and clinical application in genetic epileptic and developmental encephalopathies? <i>S. Troisi</i>
10.30	Discussion
10.45	Coffee Break
SESSION 2: DEMENTIA, SLEEP AND MOOD DISORDERS <i>Chair: P. Barone - F. Habetswallner - L. Sinisi</i>	
11.00	Are the new anti-amyloid drugs cost effective? <i>S. Esposito</i>
11.15	Does zoster immunization reduce the incidence of dementia? <i>S. Peluso</i>
11.30	Lifestyle factors can protect against dementia through amyloid metabolism? <i>A. Sagnelli</i>
11.45	LECTURE: Long-term use of antidepressants: do they alter brain function over time? <i>A. Iavarone</i>
12.05	Sleep disorders and insomnia as a prodromal symptom of dementia: is neurodegeneration the cause or the consequence? <i>F. Conte</i>
12.20	Familial amyloid polyneuropathy: should neurologist screen for it all the polyneuropathies without etiology? <i>S. Tozza</i>
12.35	Discussion
13.00	Lunch Break

SESSION 3: NEUROIMMUNOLOGY AND PARKINSON DISEASE
Chair: S. Bonavita - F. Manganelli - A. Tessitore

14.30	iMAO vs iCOMT: What is the best first adjunctive therapy to L- dopa in fluctuating PD patients? <i>M. Amboni</i>
14.45	Should FOS LEVODOPA displace LCG in the next future? <i>K. Longo</i>
15.00	Have monoclonal antibodies changed the scene in myasthenia gravis? <i>A. Bisecco</i>
15.15	Is the widespread use of anti-CD20 therapies in multiple sclerosis transforming disease management, or are we underestimating long-term risks like immune reconstitution, infections, and future treatment challenges? <i>R. Capuano</i>
15.30	L'INTERVISTA: MS vs. NMO vs. MOGAD: Are We Redefining CNS Demyelinating Disorders? <i>R. Lanzillo e A. Gallo</i>
15.50	Discussion

SESSION 4: APERITIF TIME HEADACHES AND INTRACRANIAL PRESSURE DISORDERS
Chair: A. Russo - F. D'Onofrio - B. Ronga

16.00	Which is the best option in complicated IIH: CSF Shunting or Venous Stenting? <i>A. Ranieri</i>
16.15	Idiopathic Intracranial Hypertension and Spontaneous Intracranial Hypotension: single or distinct diseases? <i>M. Silvestro</i>
16.30	Can Gepants and mAb on CGRP solve the problem of refractory migraine? <i>P. Ripa</i>
16.45	Discussion
17.00	Highlights of the day. Poll results and conclusive remarks
17.30 - 18.00	Learning questionnaire

Razionale

Few medical specialties have undergone such groundbreaking changes in such a short period as Neurology. It has transitioned from a hazy and somewhat mystical, yet nihilistic, field to a modern, scientific, and often treatable medical area. Moreover, general diagnostic and treatment strategies have frequently given way to tailored approaches. Indeed, thanks to major advancements in the diagnosis and treatment of cerebrovascular diseases, particularly ischemic stroke, the most common neurological disease, we can now halve stroke-related disability. The advent of monoclonal antibodies has dramatically improved the quality of life for people suffering from episodic and chronic migraines and is poised to revolutionize the treatment of dementias. Multiple sclerosis and neuro-immunological CNS and PNS disorders can now benefit from modern diagnostic criteria and innovative care, significantly modifying the course of these diseases. Furthermore, new and more tolerable drugs have expanded treatment options for epilepsy, and new frontiers are being explored in the management of advanced Parkinson's disease. However... Is it all so clear? Is there sufficient and robust evidence supporting our everyday clinical decision-making? The aim of this conference is to shed light on many persisting grey areas in Neurology. Experts in specific fields will take turns, presenting their viewpoints and, whenever possible, attempting to address your doubts in a friendly and engaging discussion.

SCHEDA DI ISCRIZIONE 20 maggio 2025

La scheda compilata va inviata entro il 13 maggio 2025 per e-mail a: congressi@ecmnetwork.it o può iscriversi direttamente sul sito www.ecmnetwork.it. L'effettiva iscrizione dovrà essere effettuata in sede congressuale entro le ore 08.30. Per la certificazione ECM è indispensabile compilare in modo chiaro e leggibile sia la Scheda di Iscrizione che il Modulo ECM (in particolare codice fiscale ed indirizzo email) poichè l'attestato ECM verrà inviato esclusivamente per posta elettronica.

Nome

Cognome

Codice Fiscale

Luogo di nascita Data di nascita

Indirizzo

Città Cap

Tel. / Cell.

e-mail
(obbligatoria per ricevere l'attestato ECM)

Professione

Specializzazione

Ente di Appartenenza

☐ Libero Professionista ☐ Dipendente ☐ Convenzionato

Informazione e consenso ex Articoli 9, 10, 11 Legge 675/96 (Legge sulla Privacy)

Data Firma